BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 24890748)

  • 21. Epidermal growth factor-like ligands differentially up-regulate matrix metalloproteinase 9 in head and neck squamous carcinoma cells.
    O-charoenrat P; Modjtahedi H; Rhys-Evans P; Court WJ; Box GM; Eccles SA
    Cancer Res; 2000 Feb; 60(4):1121-8. PubMed ID: 10706134
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Differential expression patterns of MMPs and their role in the invasion of epithelial premalignant tumors and invasive cutaneous squamous cell carcinoma.
    Roh MR; Zheng Z; Kim HS; Kwon JE; Jeung HC; Rha SY; Chung KY
    Exp Mol Pathol; 2012 Apr; 92(2):236-42. PubMed ID: 22305927
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Heat shock protein 90 (HSP90) is overexpressed in p16-negative oropharyngeal squamous cell carcinoma, and its inhibition in vitro potentiates the effects of chemoradiation.
    Patel K; Wen J; Magliocca K; Muller S; Liu Y; Chen ZG; Saba N; Diaz R
    Cancer Chemother Pharmacol; 2014 Nov; 74(5):1015-22. PubMed ID: 25205430
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Oncolytic activity of reovirus in HPV positive and negative head and neck squamous cell carcinoma.
    Cooper T; Biron VL; Fast D; Tam R; Carey T; Shmulevitz M; Seikaly H
    J Otolaryngol Head Neck Surg; 2015 Feb; 44(1):8. PubMed ID: 25890191
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anti-invasion and anti-tumor growth effect of doxycycline treatment for human oral squamous-cell carcinoma--in vitro and in vivo studies.
    Shen LC; Chen YK; Lin LM; Shaw SY
    Oral Oncol; 2010 Mar; 46(3):178-84. PubMed ID: 20036604
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Expression of matrix metalloproteinase-2 and -9 and membrane-type 1 matrix metalloproteinase in melanocytic tumors of dogs and canine melanoma cell lines.
    Docampo MJ; Cabrera J; Rabanal RM; Bassols A
    Am J Vet Res; 2011 Aug; 72(8):1087-96. PubMed ID: 21801067
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Imatinib mesylate (STI571; Glivec)--a new approach in the treatment of biliary tract cancer?
    Wiedmann M; Kreth F; Feisthammel J; Deininger M; Mössner J; Caca K
    Anticancer Drugs; 2003 Oct; 14(9):751-60. PubMed ID: 14551510
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Expression of matrix metalloproteinase (MMP)-2, MMP-9, MMP-13, and MT1-MMP in skin tumors of human papillomavirus type 8 transgenic mice.
    Akgül B; Pfefferle R; Marcuzzi GP; Zigrino P; Krieg T; Pfister H; Mauch C
    Exp Dermatol; 2006 Jan; 15(1):35-42. PubMed ID: 16364029
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of cytokines on matrix metalloproteinase expression in oral squamous cell carcinoma in vitro.
    Sundelin K; Roberg K; Grénman R; Håkansson L
    Acta Otolaryngol; 2005 Jul; 125(7):765-73. PubMed ID: 16012040
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Expression of matrix metalloproteinases (MMP-2, MMP-9, MT1-MMP) and their inhibitors (TIMP-1, TIMP-2) in common epithelial tumors of the ovary.
    Sakata K; Shigemasa K; Nagai N; Ohama K
    Int J Oncol; 2000 Oct; 17(4):673-81. PubMed ID: 10995877
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Expression and activation of matrix metalloproteinase-2 (MMP-2) and its co-localization with membrane-type 1 matrix metalloproteinase (MT1-MMP) correlate with melanoma progression.
    Hofmann UB; Westphal JR; Zendman AJ; Becker JC; Ruiter DJ; van Muijen GN
    J Pathol; 2000 Jul; 191(3):245-56. PubMed ID: 10878545
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cortactin is an essential regulator of matrix metalloproteinase secretion and extracellular matrix degradation in invadopodia.
    Clark ES; Whigham AS; Yarbrough WG; Weaver AM
    Cancer Res; 2007 May; 67(9):4227-35. PubMed ID: 17483334
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Imatinib mesylate (STI571) interference with growth of neuroectodermal tumour cell lines does not critically involve c-Kit inhibition.
    Te Kronnie G; Timeus F; Rinaldi A; Crescenzio N; Spinelli M; Rosolen A; Ricotti E; Basso G
    Int J Mol Med; 2004 Sep; 14(3):373-82. PubMed ID: 15289888
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Is p16 immunohistochemistry a more cost-effective method for identification of human papilloma virus-associated head and neck squamous cell carcinoma?
    Thomas J; Primeaux T
    Ann Diagn Pathol; 2012 Apr; 16(2):91-9. PubMed ID: 22197546
    [TBL] [Abstract][Full Text] [Related]  

  • 35. STI-571 (Gleevec) potentiates the effect of cisplatin in inhibiting the proliferation of head and neck squamous cell carcinoma in vitro.
    Wang-Rodriguez J; Lopez JP; Altuna X; Chu TS; Weisman RA; Ongkeko WM
    Laryngoscope; 2006 Aug; 116(8):1409-16. PubMed ID: 16885745
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Detection of human papillomavirus-16 in fine-needle aspirates to determine tumor origin in patients with metastatic squamous cell carcinoma of the head and neck.
    Begum S; Gillison ML; Nicol TL; Westra WH
    Clin Cancer Res; 2007 Feb; 13(4):1186-91. PubMed ID: 17317828
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Membrane type I-matrix metalloproteinase-mediated degradation of type I collagen by oral squamous cell carcinoma cells.
    Aznavoorian S; Moore BA; Alexander-Lister LD; Hallit SL; Windsor LJ; Engler JA
    Cancer Res; 2001 Aug; 61(16):6264-75. PubMed ID: 11507081
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Matrix metalloproteases in head and neck cancer.
    Rosenthal EL; Matrisian LM
    Head Neck; 2006 Jul; 28(7):639-48. PubMed ID: 16470875
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhibition of head and neck squamous cell carcinoma growth and invasion by the calcium influx inhibitor carboxyamido-triazole.
    Wu Y; Palad AJ; Wasilenko WJ; Blackmore PF; Pincus WA; Schechter GL; Spoonster JR; Kohn EC; Somers KD
    Clin Cancer Res; 1997 Nov; 3(11):1915-21. PubMed ID: 9815580
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeted Therapies in HPV-positive and -negative HNSCC - Alteration of EGFR and VEGFR-2 Expression In Vitro.
    Kramer B; Hock C; Birk R; Sauter A; Stuck BA; Hörmann K; Schultz JD; Aderhold C
    Anticancer Res; 2016 Jun; 36(6):2799-807. PubMed ID: 27272791
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.